| Literature DB >> 31163620 |
Sandra Teresita Martín-Del-Campo1, Pablo César Martínez-Basilio2, Juan Carlos Sepúlveda-Álvarez3, Susana Estela Gutiérrez-Melchor4, Karla Deniss Galindo-Peña5, Ana Karen Lara-Domínguez6, Anaberta Cardador-Martínez7.
Abstract
Cheese whey, a byproduct of the cheese-making industry, is discarded in many countries in the environment, causing pollution. This byproduct contains high-quality proteins containing encrypted biologically active peptides. The objective of this work was to evaluate the suitability of using this waste to produce bioactive peptides by enzymatic hydrolysis with a digestive enzyme. Cheese whey from white cheese (Panela cheese) was concentrated to increase total protein and hydrolyzed with trypsin. A central composite design was used to find the best conditions of pH and temperature, giving the higher antioxidant capacity and Δ Angiotensin-converting enzyme inhibition (Δ ACEI) activity. Higher biological activities were found when hydrolysis was performed at 52 °C and a pH of 8.2. The maximum value for the 2,2- diphenyl-1-picrylhydrazyl (DPPH)-scavenging activity was 26%, while the higher Δ ACE inhibition was 0.89. Significant correlations were found between these biological activities and the peptides separated by HPLC. The hydrophilic fraction (HI) showed highly significant correlations with the antioxidant capacity (r = 0.770) and with Δ ACE inhibition (r = 0.706). Antioxidant capacity showed a significant positive correlation with 34 peaks and Δ ACE inhibition with 33 peaks. The cheese whey was successfully used as raw material to produce peptides showing antioxidant capacity and ACEI activity.Entities:
Keywords: ACEI activity; antioxidant capacity; cheese whey; trypsin hydrolysis
Year: 2019 PMID: 31163620 PMCID: PMC6617266 DOI: 10.3390/antiox8060158
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Analysis of variance results with an α = 0.05.
| Parameter | Factor ( | Mean | Minimum | Maximum | |
|---|---|---|---|---|---|
| pH | Temperature | ||||
| % Hydrolysis | 0.002 ** | 0.230 | 66.67 | 32.82 | 100.34 |
| Soluble Protein b | 0.010 ** | 0.000 *** | 0.28 | 0.05 | 0.46 |
| Antioxidant capacity c | 0.035 * | 0.000 *** | 12.04 | 4.76 | 26.20 |
| Δ ACE inhibition d | 0.000 *** | 0.246 | 0.79 | 0.68 | 0.89 |
| AA fraction | 0.438 | 0.171 | 25,412.87 | 13,200.70 | 35,041.30 |
| Hydrophilic fraction (HI) | 0.161 | 0.000 *** | 15,602.86 | 7364.70 | 27,454.90 |
| Hydrophobic fraction (HO) | 0.890 | 0.563 | 23,738.38 | 409.50 | 372,127.00 |
| Ratio HI:HO | 0.139 | 0.071 | 2.94 | 0.03 | 20.12 |
a Significant difference at * p < 0.05, ** p < 0.01, and *** p < 0.001. b Expressed as mg/mL. c Expressed as the 2,2- diphenyl-1-picrylhydrazyl (DPPH) % discoloration. d Ratio between Angiotensin converting enzyme (ACE) peptides inhibition/captopril inhibition.
Figure 1Response surface plots of pH and temperature for (a) % of hydrolysis, (b) soluble protein (mg/mL), (c) antioxidant capacity (DPPH % discoloration), (d) Δ ACE inhibition, and (e) peptides hydrophilic fraction (HI).
Correlation table of biological activity of the produced peptides with an α = 0.05.
| Variable a | RT | Antioxidant Capacity b | Δ ACE Inhibition c | Variable | RT | Antioxidant Capacity b | Δ ACE Inhibition c |
|---|---|---|---|---|---|---|---|
| Δ ACE inhibition c | 0.516 * | P61 | 22.603 | 0.667 ** |
| ||
| AA fraction | 0.333 | 0.204 | P62 | 22.899 | −0.290 |
| |
| Hydrophilic fraction (HI) | 0.770 *** | 0.706 ** | P73 | 26.790 | 0.541 * |
| |
| Hydrophobic fraction (HO) | −0.231 | 0.005 | P74 | 27.345 | 0.745 *** | 0.374 | |
| Ratio HI:HO | −0.069 | −0.516 * | P75 | 27.623 | −0.526 * | −0.008 | |
| P2 | 2.045 | 0.379 | 0.513 * | P76 | 28.114 | 0.631 ** |
|
| P3 | 2.432 | −0.789 *** | −0.257 | P78 | 28.704 | 0.563 * | 0.121 |
| P8 | 3.759 | 0.346 | 0.576 * | P80 | 29.626 | 0.498 * | 0.363 |
| P10 | 4.103 | 0.720 *** | 0.484 * | P81 | 29.734 | 0.546 * | 0.243 |
| P11 | 4.857 | 0.746 *** | 0.573 * | P82 | 30.868 | 0.636 ** |
|
| P12 | 5.689 | 0.446 | 0.601 ** | P86 | 32.838 | 0.641 ** | 0.464 |
| P13 | 6.133 | 0.535 * | 0.565 * | P87 | 33.339 | 0.647 ** |
|
| P18 | 8.316 | 0.524 * | 0.496 * | P89 | 34.293 | 0.471 * |
|
| P19 | 8.943 | 0.591 ** | 0.616 ** | P90 | 34.590 | −0.271 | 0.022 |
| P22 | 10.204 | 0.548 * | 0.324 | P91 | 34.848 | 0.390 |
|
| P23 | 10.547 | 0.720 *** | 0.498 * | P92 | 35.479 | 0.611 ** | 0.633 ** |
| P27 | 12.367 | 0.359 | 0.475 * | P98 | 38.279 | 0.580 * | −0.014 |
| P28 | 13.195 | 0.389 | 0.514 * | P99 | 38.950 | 0.481 * | 0.018 |
| P31 | 14.097 | 0.392 | 0.569 * | P100 | 39.193 | 0.035 | 0.476 * |
| P34 | 14.893 | 0.612 ** | 0.051 | P102 | 39.876 | 0.590 * | 0.348 |
| P35 | 15.050 | 0.048 | 0.537 * | P106 | 41.778 | 0.241 | 0.494 * |
| P37 | 15.698 | 0.568 * | 0.426 | P107 | 42.052 | 0.605 ** | 0.126 |
| P39 | 16.190 | 0.519 * | 0.216 | P109 | 43.430 | 0.729 *** | 0.563 ** |
| P45 | 17.733 | 0.796 *** | 0.561 * | P110 | 44.162 | 0.771 *** | 0.168 |
| P46 | 18.131 | 0.555 * | 0.450 | P111 | 44.881 | 0.692 ** | 0.250 |
| P48 | 18.768 | 0.520 * | 0.593 ** | P114 | 46.743 | 0.831 *** | 0.590 ** |
| P51 | 19.534 | 0.580 * | 0.595 ** | P116 | 48.529 | 0.290 | 0.503 * |
| P54 | 20.964 | 0.466 | 0.687 ** | P119 | 53.330 | 0.344 | 0.646 ** |
| P56 | 21.355 | 0.422 | 0.475 * | P120 | 58.930 | 0.335 | 0.506 * |
a Significant correlation at * p < 0.05, ** p < 0.01, and *** p < 0.001. b Expressed as DPPH% discoloration. c Ratio between ACE peptides inhibition/captopril inhibition.